Noninvasive ventilation: has Pandora’s box been opened?
Authors Manuel A, Russell RE, Jones Q
Published 24 February 2010 Volume 2010:5 Pages 55—56
Ari Manuel1, Richard EK Russell2, Quentin Jones3
1Department of Respiratory Medicine, High Wycombe Hospital, Bucks, UK; 2Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 3Specialist Registrar, Department of Respiratory Medicine, Churchill Hospital, Oxford
Exacerbations of COPD are the largest single cause of hospital admission with respiratory disease, and are frequently associated with impaired gas exchange and mortality rates of up to 14%. Acute hypercapnic respiratory failure leads to admissions to intensive care units with a mortality rate of 59% at one year. Noninvasive ventilation (NIV) is a well established and validated therapy for acidotic hypercapnia respiratory failure in COPD, a leading cause of global mortality and morbidity. The use of NIV in patients with acute type II or chronic respiratory failure has increased over the past 10 years.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]